|
1
|
Lee UE and Friedman SL: Mechanisms of
hepatic fibrogenesis. Best Pract Res Clinical Gastroenterol.
25:195–206. 2011. View Article : Google Scholar
|
|
2
|
Friedman SL: Mechanisms of hepatic
fibrogenesis. Gastroenterology. 134:1655–1669. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Popov Y and Schuppan D: Targeting liver
fbrosis: Strategies for development and validation of antifibrotic
therapies. Hepatology. 50:1294–1306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brown-Clay JD, Shenoy DN, Timofeeva O,
Kallakury BV, Nandi AK and Banerjee PP: PBK/TOPK enhances
aggressive phenotype in prostate cancer via
β-catenin-TCF/LEF-mediated matrix metalloproteinases production and
invasion. Oncotarget. 6:15594–15609. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang CY, Yuan WG, He P, Lei JH and Wang
CX: Liver fibrosis and hepatic stellate cells: Etiology,
pathological hallmarks and therapeutic targets. World J
Gastroenterol. 22:10512–10522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bataller R and Brenner DA: Liver fibrosis.
J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schuppan D: Liver fibrosis: Common
mechanisms and antifibrotic therapies. Clin Res Hepatol
Gastroenterol. 39 (Suppl):S51–S59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koyama Y, Xu J, Liu X and Brenner DA: New
developments on the treatment of liver fibrosis. Dig Dis.
34:589–596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Samuelsen AB: The traditional uses,
chemical constituents and biological activities of plantago major
L. A review. J Ethnopharmacol. 71:1–21. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang DF, Tang YF, Nie SP, Wan Y, Xie MY
and Xie XM: Effect of phenylethanoid glycosides and polysaccharides
from the seed of Plantago asiatica L. on the maturation of murine
bone marrow-derived dendritic cells. Eur J Pharmacol. 620:105–111.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu H, Zhao G, Jiang K, Chen X, Zhu Z, Qiu
C, Li C and Deng G: Plantamajoside ameliorates
lipopolysaccharide-induced acute lung injury via suppressing NF-κB
and MAPK activation. Int Immunopharmacol. 35:315–322. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pei S, Yang X, Wang H, Zhang H, Zhou B,
Zhang D and Lin D: Plantamajoside, a potential anti-tumor herbal
medicine inhibits breast cancer growth and pulmonary metastasis by
decreasing the activity of matrix metalloproteinase-9 and −2. BMC
Cancer. 15:9652015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li X, Chen D, Li M, Gao X, Shi G and Zhao
H: Plantamajoside inhibits lipopolysaccharide-induced
epithelial-mesenchymal transition through suppressing the
NF-κB/IL-6 signaling in esophageal squamous cell carcinoma cells.
Biomed Pharmacother. 102:1045–1051. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ma C and Ma W: Plantamajoside inhibits
lipopolysaccharide-induced MUC5AC expression and inflammation
through suppressing the PI3K/Akt and NF-κB signaling pathways in
human airway epithelial cells. Inflammation. 41:795–802. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Son WR, Nam MH, Hong CO, Kim Y and Lee KW:
Plantamajoside from Plantago asiatica modulates human umbilical
vein endothelial cell dysfunction by glyceraldehyde-induced AGEs
via MAPK/NF-κB. BMC Complement Altern Med. 17:662017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Puche JE, Saiman Y and Friedman SL:
Hepatic stellate cells and liver fibrosis. Compr Physiol.
3:1473–1492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Higashi T, Friedman SL and Hoshida Y:
Hepatic stellate cells as key target in liver fibrosis. Adv Drug
Deliv Rev. 121:27–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Panebianco C, Oben JA, Vinciguerra M and
Pazienza V: Senescence in hepatic stellate cells as a mechanism of
liver fibrosis reversal: A putative synergy between retinoic acid
and PPAR-gamma signalings. Clin Exp Med. 17:269–280. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin X, Kong LN, Huang C, Ma TT, Meng XM,
He Y, Wang QQ and Li J: Hesperetin derivative-7 inhibits
PDGF-BB-induced hepatic stellate cell activation and proliferation
by targeting Wnt/β-catenin pathway. Int Immunopharmacol.
25:311–320. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu X, Zhi F, Lun W, Deng Q and Zhang W:
Baicalin inhibits PDGF-BB-induced hepatic stellate cell
proliferation, apoptosis, invasion, migration and activation via
the miR-3595/ACSL4 axis. Int J Mol Med. 41:1992–2002.
2018.PubMed/NCBI
|
|
21
|
Yang Y, Chen XX, Li WX, Wu XQ, Huang C,
Xie J, Zhao YX, Meng XM and Li J: EZH2-mediated repression of Dkk1
promotes hepatic stellate cell activation and hepaticfibrosis. J
Cell Mol Med. 21:2317–2328. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang L, Zhang CZ and Zhu QJ: Kangxian
ruangan keli inhibits hepatic stellate cell proliferation mediated
by PDGF. World J Gastroenterol. 9:2050–2053. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schuppan D: Structure of the extracellular
matrix in normal and fibrotic liver: Collagens and glycoproteins.
Semin Liver Dis. 10:1–10. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Anthony PP, Ishak KG, Nayak NC, Poulsen
HE, Scheuer PJ and Sobin LH: The morphology of cirrhosis.
Recommendations on defnition, nomenclature, and classifcation by a
working group sponsored by the world health organization. J Clin
Pathol. 31:395–414. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mormone E, George J and Nieto N: Molecular
pathogenesis of hepatic fbrosis and current therapeutic approaches.
Chem Biol Interact. 193:225–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han YP, Zhou L, Wang J, Xiong S, Garner
WL, French SW and Tsukamoto H: Essential role of matrix
metalloproteinases in interleukin-1-induced myofibroblastic
activation of hepatic stellate cell in collagen. J Biol Chem.
279:4820–4828. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Altamirano-Barrera A, Barranco-Fragoso B
and Méndez-Sánchez N: Management strategies for liver fibrosis. Ann
Hepatol. 16:48–56. 2017. View Article : Google Scholar
|
|
29
|
Gressner AM: Transdifferentiation of
hepatic stellate cells (Ito cells) to myofibroblasts: A key event
in hepatic fibrogenesis. Kidney Int. 54 (Suppl):S39–S45. 1996.
|
|
30
|
Drescher HK, Schumacher F, Schenker T,
Baues M, Lammers T, Hieronymus T, Trautwein C, Streetz KL and Kroy
DC: c-Met signaling protects from nonalcoholic
steatohepatitis-(NASH-) induced fibrosis in different liver cell
types. Oxid Med Cell Longev 2018. 69574972018.
|
|
31
|
Wong L, Yamasaki G, Johnson RJ and
Friedman SL: Induction of beta-platelet-derived growth factor
receptor in rat hepatic lipocytes during cellular activation in
vivo and in culture. J Clin Invest. 94:1563–1569. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu CI, Hoffman JA, Shy BR, Ford EM, Fuchs
E, Nguyen H and Merrill BJ: Function of Wnt/β-catenin in
counteracting Tcf3 repression through the Tcf3-β-catenin
interaction. Development. 139:2118–2129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fang L, Zhan S, Huang C, Cheng X, Lv X, Si
H and Li J: TRPM7 channel regulates PDGF-BB-induced proliferation
of hepatic stellate cells via PI3K and ERK pathways. Toxicol Appl
Pharmacol. 272:713–725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tao H, Huang C, Yang JJ, Ma TT, Bian EB,
Zhang L, Lv XW, Jin Y and Li J: MeCP2 controls the expression of
RASAL1 in the hepatic fibrosis in rats. Toxicology. 290:327–333.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Woodhoo A, Iruarrizaga-Lejarreta M, Beraza
N, García-Rodríguez JL, Embade N, Fernández-Ramos D, Martínez-López
N, Gutiérrez-De Juan V, Arteta B, Caballeria J, et al: Human
antigen R contributes to hepatic stellate cell activation and liver
fibrosis. Hepatology. 56:1870–1882. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
El-Mihi KA, Kenawy HI, El-Karef A,
Elsherbiny NM and Eissa LA: Naringin attenuates
thioacetamide-induced liver fibrosis in rats through modulation of
the PI3K/Akt pathway. Life Sci. 187:50–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen Q, Chen L, Wu X, Zhang F, Jin H, Lu
C, Shao J, Kong D, Wu L and Zheng S: Dihydroartemisinin prevents
liver fibrosis in bile duct ligated rats by inducing hepatic
stellate cell apoptosis through modulating the PI3K/Akt pathway.
IUBMB Life. 68:220–231. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang J, Chu ES, Chen HY, Man K, Go MY,
Huang XR, Lan HY, Sung JJ and Yu J: microRNA-29b prevents liver
fibrosis by attenuating hepatic stellate cell activation and
inducing apoptosis through targeting PI3K/AKT pathway. Oncotarget.
6:7325–7338. 2015.PubMed/NCBI
|
